Effects of the dopamine depleting agent tetrabenazine on detailed temporal parameters of effort-related choice responding.
behavioral economics
dopamine
effort
reinforcement
work
Journal
Journal of the experimental analysis of behavior
ISSN: 1938-3711
Titre abrégé: J Exp Anal Behav
Pays: United States
ID NLM: 0203727
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
29
01
2022
received:
15
10
2021
accepted:
31
01
2022
pubmed:
29
3
2022
medline:
12
5
2022
entrez:
28
3
2022
Statut:
ppublish
Résumé
The dopamine-depleting agent tetrabenazine alters effort-based choice, suppressing food-reinforced behaviors with high response requirements, while increasing selection of low-cost options. In the present experiments, rats were tested on a concurrent fixed ratio 5/chow feeding choice task, in which high-carbohydrate Bio-serv pellets reinforced lever pressing and lab chow was concurrently available. Detailed timing of lever pressing was monitored with an event recording system, and the temporal characteristics of operant behavior seen after 1.0 mg/kg tetrabenazine or vehicle injections were analyzed. Tetrabenazine shifted choice, decreasing lever pressing but increasing chow intake. There was a small effect on the interresponse-time distribution within ratios, but marked increases in the total duration of pauses in responding. The postreinforcement-pause (PRP) distribution was bimodal, but tetrabenazine did not increase the duration of PRPs. Tetrabenazine increased time feeding and duration and number of feeding bouts, but did not affect feeding rate or total time spent lever pressing for pellets and consuming chow. Thus, TBZ appears to predominantly affect the relative allocation of lever pressing versus chow, with little alteration in consummatory motor acts involved in chow intake. Tetrabenazine is used to model motivational symptoms in psychopathology, and these effects in rats could have implications for psychiatric research.
Identifiants
pubmed: 35344599
doi: 10.1002/jeab.754
pmc: PMC9531143
mid: NIHMS1789686
doi:
Substances chimiques
Dopamine
VTD58H1Z2X
Tetrabenazine
Z9O08YRN8O
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-345Subventions
Organisme : NIMH NIH HHS
ID : R01 MH121350
Pays : United States
Informations de copyright
© 2022 Society for the Experimental Analysis of Behavior.
Références
Neuropharmacology. 2021 Feb 1;183:108325
pubmed: 32956676
Neuropsychopharmacology. 2016 Feb;41(3):686-94
pubmed: 26105139
Psychopharmacology (Berl). 2015 Apr;232(7):1313-23
pubmed: 25323625
J Exp Anal Behav. 1991 Nov;56(3):445-54
pubmed: 1774538
Clin Ther. 2012 Jul;34(7):1487-504
pubmed: 22749259
Psychopharmacology (Berl). 2009 Apr;203(3):489-99
pubmed: 19048234
Pharmacol Biochem Behav. 2015 Aug;135:217-26
pubmed: 26022661
J Exp Anal Behav. 1995 Nov;64(3):313-29
pubmed: 16812774
Neuropharmacology. 2016 Oct;109:270-280
pubmed: 27329556
Psychopharmacology (Berl). 2008 Mar;196(4):565-74
pubmed: 18004546
J Comp Physiol Psychol. 1975 Jan;88(1):104-9
pubmed: 1120788
Psychopharmacology (Berl). 2021 Dec;238(12):3357-3373
pubmed: 34498115
J Exp Anal Behav. 2012 Jan;97(1):125-46
pubmed: 22287808
Neuropsychopharmacology. 2008 Jul;33(8):1966-79
pubmed: 17805307
J Abnorm Psychol. 2012 Aug;121(3):553-8
pubmed: 22775583
Neuron. 2012 Nov 8;76(3):470-85
pubmed: 23141060
Psychopharmacology (Berl). 1986;88(1):18-23
pubmed: 3080774
Psychopharmacology (Berl). 2020 Nov;237(11):3459-3470
pubmed: 32770257
Psychopharmacology (Berl). 1992;107(2-3):160-74
pubmed: 1615120
Physiol Behav. 1980 Jul;25(1):135-7
pubmed: 7413809
Pharmacol Biochem Behav. 1993 Mar;44(3):605-10
pubmed: 8451265
Front Pharmacol. 2019 Jun 28;10:682
pubmed: 31316379
Neuroscience. 1990;39(1):17-24
pubmed: 2128534
Psychopharmacology (Berl). 2000 Sep;152(1):67-73
pubmed: 11041317
J Neurosci. 2013 Dec 4;33(49):19120-30
pubmed: 24305809
Psychopharmacology (Berl). 2007 Apr;191(3):461-82
pubmed: 17225164
Biol Psychiatry. 2013 Jul 15;74(2):130-6
pubmed: 23394903
Eur J Pharmacol. 1984 Jul 20;102(3-4):425-30
pubmed: 6489435
Brain. 2016 May;139(Pt 5):1325-47
pubmed: 27189581
Psychopharmacology (Berl). 1994 Dec;116(4):529-37
pubmed: 7701059
Am J Geriatr Pharmacother. 2010 Aug;8(4):331-73
pubmed: 20869622
J Exp Anal Behav. 1988 Nov;50(3):419-40
pubmed: 3209958
Behav Brain Res. 2002 Dec 2;137(1-2):3-25
pubmed: 12445713
Pharmacol Biochem Behav. 2016 Sep;148:84-91
pubmed: 27296079
Neural Netw. 2006 Oct;19(8):1302-14
pubmed: 16949252
Pharmacol Rev. 2018 Oct;70(4):747-762
pubmed: 30209181
Front Behav Neurosci. 2021 Jul 09;15:700182
pubmed: 34305547
Behav Processes. 2007 Jun;75(2):206-12
pubmed: 17398038
PLoS One. 2014 Jun 17;9(6):e99320
pubmed: 24937131
J Pharmacol Exp Ther. 2003 Apr;305(1):1-8
pubmed: 12649346
PLoS One. 2012;7(10):e47934
pubmed: 23110135
Psychopharmacology (Berl). 2020 Jan;237(1):33-43
pubmed: 31392358
Neuropsychiatr Dis Treat. 2010 Oct 05;6:657-65
pubmed: 20957126
Behav Brain Res. 2006 Aug 10;171(2):350-4
pubmed: 16697474
J Exp Anal Behav. 2001 Jan;75(1):93-106
pubmed: 11256869
Curr Opin Pharmacol. 2005 Feb;5(1):34-41
pubmed: 15661623
Pharmacol Biochem Behav. 2010 Nov;97(1):179-84
pubmed: 20713079
Behav Processes. 2016 Jun;127:3-17
pubmed: 26899746
Cogn Affect Behav Neurosci. 2008 Dec;8(4):375-89
pubmed: 19033236
Physiol Behav. 1980 Jul;25(1):139-41
pubmed: 7413810
Cereb Cortex. 2009 Oct;19(10):2240-7
pubmed: 19131436
Psychopharmacology (Berl). 2016 Mar;233(6):949-60
pubmed: 26694811
Psychopharmacology (Berl). 2002 Apr;160(4):371-80
pubmed: 11919664
Psychopharmacology (Berl). 1991;104(4):515-21
pubmed: 1780422
BMC Neurol. 2009 Dec 18;9:62
pubmed: 20021666